10-2028
|
A Multicenter, Adaptive, Randomized, Blinded Controlled
A Multicenter, Adaptive, Randomized, Blinded Controlled
|
10-2028
|
A Phase I/III Randomized, Double-blind Study to Evaluate
A Phase I/III Randomized, Double-blind Study to Evaluate
|
02-2028
|
A Multicenter, Adaptive, Randomized, Controlled Trial Pl
A Multicenter, Adaptive, Randomized, Controlled Trial Pl
|
09-2027
|
Reparixin 1200 mg three times a day as add-on therapy t
Reparixin 1200 mg three times a day as add-on therapy t
|
05-2027
|
Technology-based assessments and intervention to reduce
Technology-based assessments and intervention to reduce
|
03-2027
|
Mechanisms, Markers, and Risk Factors in Friedreich's At
Mechanisms, Markers, and Risk Factors in Friedreich's At
|
11-2026
|
ARLG Pneumonia Direct Pilot Synopsis
ARLG Pneumonia Direct Pilot Synopsis
|
10-2026
|
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED
|
10-2026
|
Protocol: C4671002
Protocol: C4671002
|
10-2026
|
Protocol: C4671006
Protocol: C4671006
|
09-2026
|
Protocol: C4671005
Protocol: C4671005
|
06-2026
|
Protocol: INSIGHT 016
Protocol: INSIGHT 016
|
06-2026
|
Evaluation of the Feasibility and Reproducibility of 2
Evaluation of the Feasibility and Reproducibility of 2
|
03-2026
|
A Phase 2b, Multicenter, Randomized, Open-Label, Assesso
A Phase 2b, Multicenter, Randomized, Open-Label, Assesso
|
03-2026
|
Brii_: Adaptive Platform Treatment Trial for Outpatients
Brii_: Adaptive Platform Treatment Trial for Outpatients
|
12-2025
|
A Phase 2 Study to Assess the Virologic Efficacy of REGN
A Phase 2 Study to Assess the Virologic Efficacy of REGN
|
10-2025
|
Phase II: Adaptive Platform Treatment Trial for Outpatie
Phase II: Adaptive Platform Treatment Trial for Outpatie
|
08-2025
|
ID NOW¿ COVID-19
ID NOW¿ COVID-19
|
06-2025
|
HB409 Clinical Medical Directors
HB409 Clinical Medical Directors
|
03-2025
|
Protocol #6R88-COV-2040
Protocol #6R88-COV-2040
|
03-2025
|
Component A Regional Training Center: Subcomponent A1. S
Component A Regional Training Center: Subcomponent A1. S
|
07-2024
|
A Phase 1b/2a, Randomized, Double-Blind, Placebo Control
A Phase 1b/2a, Randomized, Double-Blind, Placebo Control
|
06-2024
|
Clinical Medical Director (HB399)
Clinical Medical Director (HB399)
|
06-2024
|
Public Health Medical Officer (HB400)
Public Health Medical Officer (HB400)
|
06-2024
|
Protocol: AudibleHealth DX
Protocol: AudibleHealth DX
|
06-2024
|
Protocol: CoVPN 3006
Protocol: CoVPN 3006
|
04-2024
|
A5332: Randomized Trial to Prevent Vascular Events in HI
A5332: Randomized Trial to Prevent Vascular Events in HI
|
03-2024
|
A randomized, double-blind, placebo-controlled, multicen
A randomized, double-blind, placebo-controlled, multicen
|
09-2023
|
Disease Intervention Specialist Training Academy (DISTA)
Disease Intervention Specialist Training Academy (DISTA)
|
08-2023
|
Red Carpet Entry Program Implementation Evaluation
Red Carpet Entry Program Implementation Evaluation
|
06-2023
|
Physician's Oversight Contract (HB394)
Physician's Oversight Contract (HB394)
|
06-2023
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled
|
06-2023
|
A Randomized, Double-Blind, Placebo Controlled, Trial to
A Randomized, Double-Blind, Placebo Controlled, Trial to
|
06-2023
|
R10933-10987-COV-2067
R10933-10987-COV-2067
|
06-2023
|
R10933-10987-COV-2066
R10933-10987-COV-2066
|
01-2023
|
Synairgen _Phase III: Adaptive Platform Treatment Trial
Synairgen _Phase III: Adaptive Platform Treatment Trial
|
05-2022
|
Therapeutics for Inpatients with COVID-19 (TICO or ACT
Therapeutics for Inpatients with COVID-19 (TICO or ACT
|
05-2022
|
Therapeutics for Inpatients with COVID-19 or ITAC TO 10
Therapeutics for Inpatients with COVID-19 or ITAC TO 10
|
05-2022
|
International COVID-19 Observational Study TO 8
International COVID-19 Observational Study TO 8
|
03-2022
|
(UFlorida sub, R01): Health Outcomes and Cognitive Effec
(UFlorida sub, R01): Health Outcomes and Cognitive Effec
|
12-2021
|
Consequences of Marijuana Use on Inflammatory Pathways i
Consequences of Marijuana Use on Inflammatory Pathways i
|
12-2021
|
Consequences of Marijuana Use on Inflammatory Pathways i
Consequences of Marijuana Use on Inflammatory Pathways i
|
09-2021
|
Phase 2/3 Randomized, Placebo-Controlled, Double-Blind
Phase 2/3 Randomized, Placebo-Controlled, Double-Blind
|
06-2021
|
Toxoplasma Gondii cAMP-Dependent Kinase PKAc3 Regulation of Bradzoite Formation
Toxoplasma Gondii cAMP-Dependent Kinase PKAc3 Regulation of Bradzoite Formation
|
08-2020
|
Consequences of Marijuana Use on Inflammatory Pathways i
Consequences of Marijuana Use on Inflammatory Pathways i
|
05-2020
|
U01: Randomized Trial to Prevent Vascular Events in HIV-
U01: Randomized Trial to Prevent Vascular Events in HIV-
|
08-2019
|
Positive Health Check Evaluation Trial
Positive Health Check Evaluation Trial
|
06-2019
|
(FDOH, HB376): Physician Oversight, Medical Director & Research Coordination
(FDOH, HB376): Physician Oversight, Medical Director & Research Coordination
|
05-2019
|
Composition and Formation of the Cyst Wall
Composition and Formation of the Cyst Wall
|
02-2019
|
Cardiovascular Disease Risk in HIV-Infected Women: Sex-S
Cardiovascular Disease Risk in HIV-Infected Women: Sex-S
|
04-2016
|
Randomized Trail to Prevent Vascular Events in HIV-REPRIEVE (A5332) U01 HL 12336 and U01HL123339)
Randomized Trail to Prevent Vascular Events in HIV-REPRIEVE (A5332) U01 HL 12336 and U01HL123339)
|
02-2016
|
Protocol#EMR 200147-500
Protocol#EMR 200147-500
|
02-2016
|
Protocol# 96615
Protocol# 96615
|
05-2014
|
Protocol#B1851032 (6115A1-4007)
Protocol#B1851032 (6115A1-4007)
|
03-2014
|
Protocol #P04875-37
Protocol #P04875-37
|
08-2012
|
HIV Research Network
HIV Research Network
|
06-2012
|
Protocol #ACH443-015
Protocol #ACH443-015
|
06-2012
|
Protocol #PO4889-61
Protocol #PO4889-61
|
03-2012
|
Protocol #123
Protocol #123
|
09-2011
|
HIV Research Network
HIV Research Network
|
02-2011
|
Protocol #TMC114-C211
Protocol #TMC114-C211
|
08-2010
|
Protocol #IISP-33107
Protocol #IISP-33107
|
05-2010
|
Stratergic Timing of of Antiretroviral Therapy (START)
Stratergic Timing of of Antiretroviral Therapy (START)
|
03-2008
|
Continuation of A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (the SMART Study).
Continuation of A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (the SMART Study).
|